PD-1-IN-17 free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206957

CAS#: 1673560-66-1

Description: PD-1-IN-17 has CAS#CAS:1673560-66-1, which is a programmed cell death-1 (PD-1) inhibitor. PD-1-IN-17 was first reported in patent WO2015033301A1, (Compound 4), inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 may be related to CA-170 (AUPM170), which is a potent PD-1 inhibitor and curreently under clinical trials.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 385 2 Weeks
10mg USD 650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-28. Prices are subject to change without notice.

PD-1-IN-17 free base is in stock.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 206957
Name: PD-1-IN-17 free base
CAS#: 1673560-66-1
Chemical Formula: C13H22N6O7
Exact Mass: 374.155
Molecular Weight: 374.354
Elemental Analysis: C, 41.71; H, 5.92; N, 22.45; O, 29.92

Related CAS #: 1673560-66-1   1673534-76-3   PD-1-IN-17 TFA    

Synonym: PD-1-IN-17 free base; PD-1-IN17; CA-170; CA-170; CA-170; AUPM 170; AUPM-170; AUPM170; PD1-IN-1. PD-L1/PD-L2/VISTA antagonist, PD-1-IN 17;

IUPAC/Chemical Name: (((S)-4-amino-1-(5-((1S,2R)-1-amino-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)-4-oxobutyl)carbamoyl)-L-serine


InChi Code: InChI=1S/C13H22N6O7/c1-5(21)9(15)11-19-18-10(26-11)6(2-3-8(14)22)16-13(25)17-7(4-20)12(23)24/h5-7,9,20-21H,2-4,15H2,1H3,(H2,14,22)(H,23,24)(H2,16,17,25)/t5-,6+,7+,9+/m1/s1

SMILES Code: OC[C@@H](C(O)=O)NC(N[C@H](C1=NN=C([C@@H](N)[C@H](O)C)O1)CCC(N)=O)=O

Technical Data

Solid powder

>95% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

PD-1-IN-17 may be related to CA-170. The chemical structure of CA170 has not been disclosed as of 11/11/2019.

CA-170, also known as AUPM 170, is an orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.

CA-170 that selectively targets PD-L1 and VISTA, both of which function as negative checkpoint regulators of immune activation. CA-170 can induce effective proliferation and IFN-γ (Interferon-gamma) production (a cytokine that is produced by activated T cells and is a marker of T cell activation) by T cells that are specifically suppressed by PD-L1 or VISTA. In addition, CA-170 also appears to have anti-tumor effects similar to anti-PD-1 or anti-VISTA antibodies in multiple in vivo tumor models. Curis is currently investigating CA-170 in a Phase 1 trial in patients with advanced solid tumors and lymphomas.


1: Musielak B, Kocik J, Skalniak L, Magiera-Mularz K, Sala D, Czub M, Stec M,
Siedlar M, Holak TA, Plewka J. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor
or Not? Molecules. 2019 Aug 1;24(15). pii: E2804. doi: 10.3390/molecules24152804.
PubMed PMID: 31374878; PubMed Central PMCID: PMC6695792.

2: Shaabani S, Huizinga HPS, Butera R, Kouchi A, Guzik K, Magiera-Mularz K, Holak
TA, Dömling A. A patent review on PD-1/PD-L1 antagonists: small molecules,
peptides, and macrocycles (2015-2018). Expert Opin Ther Pat. 2018
Sep;28(9):665-678. doi: 10.1080/13543776.2018.1512706. Epub 2018 Sep 10. Review.
PubMed PMID: 30107136; PubMed Central PMCID: PMC6323140.

3: Bojadzic D, Buchwald P. Toward Small-Molecule Inhibition of Protein-Protein
Interactions: General Aspects and Recent Progress in Targeting Costimulatory and
Coinhibitory (Immune Checkpoint) Interactions. Curr Top Med Chem.
2018;18(8):674-699. doi: 10.2174/1568026618666180531092503. Review. PubMed PMID:
29848279; PubMed Central PMCID: PMC6067980.